# PERSEVERE (NCT04849364)

> Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04849364
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Bryan Schneider, MD
- Conditions: Breast Cancer; Triple Negative Breast Cancer
- Interventions: Capecitabine; Talazoparib; Pembrolizumab; Inavolisib
- Enrollment: 52
- Primary outcome: ARM 1c: Disease Free Survival (DFS) at 2 Years

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 46
- Podcasts: 30
- X threads: 25
- Bluesky threads: 1
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=persevere-nct04849364

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04849364", "email": "<work email>"}; the inbox owner confirms by the emailed link.